Abstract
Postural tachycardia syndrome (POTS) is a complex autonomic disorder with growing evidence suggesting an autoimmune contribution in a subset of patients. Therapeutic plasma exchange (TPE) is known as a potential treatment option, particularly for patients with severe or refractory disease. This editorial summarizes the clinical features of POTS, the pathophysiologic rationale for plasma exchange, and the current evidence supporting its use. Although encouraging, there is a need for larger studies and standardized protocols. Further research is warranted to clarify patient selection, treatment regimens, and long-term outcomes.